急性疾病住院患者血清白蛋白与静脉血栓栓塞风险呈负相关:APEX 试验分析
基于 APEX 试验中 7266 例有可评估 VTE 终点的内科住院患者,分析基线白蛋白与 77 天内 VTE 风险的关联。白蛋白越低 VTE 风险逐步升高(P < .0001);白蛋白最低四分位(<35 g/L)者 VTE 风险约为最高四分位(≥42 g/L)者的两倍(OR = 2.119 [95% CI, 1.592-2.820];调整后 OR = 2.079 [1.485-2.911])。将白蛋白纳入风险评估模型可改善 VTE 风险判别与重分类。
要点
- 白蛋白越低,77 天内 VTE 风险逐步升高(P < .0001)。
- 白蛋白 <35 g/L 者 VTE 风险约为 ≥42 g/L 者的两倍(调整后 OR = 2.079)。
- 白蛋白每降低 1 个标准差(5.24 g/L),VTE 风险为 1.368 倍。
核心结论
- 急性疾病住院患者低血清白蛋白与 77 天内 VTE 风险升高相关。
- 作者认为内科住院患者的 VTE 风险评估模型应考虑纳入基线白蛋白测量。
研究设计与样本
- APEX 试验(ClinicalTrials.gov 标识 NCT01583218)将内科住院患者随机分配接受延长疗程贝曲沙班或较短疗程依诺肝素,随访 77 天。
- 共 7266 例有可评估 VTE 终点的受试者获得基线白蛋白浓度。
- 评估基线白蛋白与 VTE 的关联,并调整患者特征、血栓预防措施及纤溶与炎症生物标志物(即 D-二聚体和 C 反应蛋白[CRP])。
- 通过将白蛋白纳入经过充分验证的风险评估模型来评估 VTE 风险细化。
主要发现
- 白蛋白水平越低,VTE 风险逐步升高(P < .0001)。
- 白蛋白最低四分位(<35 g/L)者发生 VTE 的比值比是最高四分位(≥42 g/L)者的两倍(OR = 2.119 [95% CI, 1.592-2.820];调整后 OR = 2.079 [1.485-2.911])。
- 白蛋白每降低 1 个标准差(5.24 g/L),VTE 的比值比为 1.368(95% CI, 1.240-1.509)。
- 与倾向评分匹配的白蛋白 ≥35 g/L 患者相比,白蛋白 <35 g/L 患者的 VTE 风险更高(OR = 1.623 [1.260-2.090];调整后 OR = 1.658 [1.209-2.272])。
- 将白蛋白纳入风险评估模型后,白蛋白测量改善了 VTE 风险判别与重分类。
关键数值与推荐
- 白蛋白最低四分位(<35 g/L)vs 最高四分位(≥42 g/L):VTE 的 OR = 2.119(95% CI, 1.592-2.820),调整后 OR = 2.079(95% CI, 1.485-2.911)。
- 白蛋白每降低 1 个标准差(5.24 g/L):VTE 的比值比为 1.368(95% CI, 1.240-1.509)。
- 白蛋白 <35 g/L vs 倾向评分匹配的白蛋白 ≥35 g/L:VTE 的 OR = 1.623(95% CI, 1.260-2.090),调整后 OR = 1.658(95% CI, 1.209-2.272)。
临床怎么用
- 作者认为,内科住院患者的 VTE 风险评估模型应考虑纳入基线白蛋白测量。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypoalbuminemia is a common finding and independent predictor for unfavorable prognosis. The prognostic value of albumin measurement for short-term VTE prediction in hospitalized patients remains unclear. In the APEX trial (ClinicalTrials.gov identifier: NCT01583218), medical inpatients were randomized to receive either extended-duration betrixaban or shorter-duration enoxaparin and followed for 77 days. Baseline albumin concentrations were obtained in 7266 subjects with evaluable VTE endpoints. The association of baseline albumin to VTE was assessed, with adjustment for patient characteristics, thromboprophylaxis, and biomarkers for fibrinolysis and inflammation (ie, D-dimer and C-reactive protein [CRP]). VTE risk refinement was evaluated by incorporation of albumin to well-validated risk assessment models. A stepwise increase in the risk of VTE (P < .0001) was observed with lower levels of albumin. Patients at the bottom albumin quartile (<35 g/L) had a two-fold greater odds for developing VTE compared with the top quartile (≥42 g/L) (OR = 2.119 [95% CI, 1.592-2.820]; adjusted OR = 2.079 [1.485-2.911]). The odds for VTE increased by 1.368 (95% CI, 1.240-1.509) times per SD decrement of albumin (5.24 g/L). Compared with the propensity score-matched pairs of patients with albumin ≥35 g/L, patients with albumin <35 g/L had a greater risk of VTE (OR = 1.623 [1.260-2.090]; adjusted OR = 1.658 [1.209-2.272]). Albumin measurement also refined VTE risk discrimination and reclassification after inclusion in the risk assessment models. In conclusion, acutely ill hospitalized patients with low serum albumin had an increased VTE risk through 77 days. VTE risk assessment models for medical inpatients should consider incorporation of baseline albumin measurement.
引用
- Chi G, Gibson CM, Liu Y, et al. Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. Am J Hematol. 2018. PMID: 30252149. doi:10.1002/ajh.25296
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。